Guangzhou Cai Zhi Lin Corporation Bei Shang Chinese Raw Medicine Co., Ltd Sustainability Profile
Guangzhou Cai Zhi Lin Corporation Bei Shang Chinese Raw Medicine Co., Ltd., commonly referred to as Bei Shang, is a prominent player in the traditional Chinese medicine industry, headquartered in Guangzhou, China. Established in the early 2000s, the company has made significant strides in the sourcing and distribution of high-quality raw medicinal herbs, catering to both domestic and international markets. Specialising in a diverse range of herbal products, Bei Shang is renowned for its commitment to quality and authenticity, ensuring that each product meets rigorous industry standards. The company’s unique approach combines traditional practices with modern quality control measures, setting it apart in a competitive landscape. With a strong market presence, Bei Shang has achieved notable recognition for its contributions to the herbal medicine sector, solidifying its reputation as a trusted supplier of Chinese raw medicine.
DitchCarbon Score
How does Guangzhou Cai Zhi Lin Corporation Bei Shang Chinese Raw Medicine Co., Ltd's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Guangzhou Cai Zhi Lin Corporation Bei Shang Chinese Raw Medicine Co., Ltd's score of 2 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Guangzhou Cai Zhi Lin Corporation Bei Shang Chinese Raw Medicine Co., Ltd currently does not have specific carbon emissions data available, as indicated by the absence of reported figures. The company is a current subsidiary of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, which may influence its climate commitments and emissions reporting. As part of its corporate family, any climate initiatives or emissions data would be inherited from Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited. However, no specific reduction targets or climate pledges have been documented for Guangzhou Cai Zhi Lin Corporation. This lack of data suggests that the company may still be in the early stages of developing its carbon management strategies or reporting frameworks. In the broader context of the pharmaceutical industry, companies are increasingly focusing on sustainability and carbon reduction, often aligning with global standards such as the Science Based Targets initiative (SBTi). It is essential for Guangzhou Cai Zhi Lin Corporation to establish clear climate commitments and reduction targets to enhance its environmental performance and align with industry best practices.
How Carbon Intensive is Guangzhou Cai Zhi Lin Corporation Bei Shang Chinese Raw Medicine Co., Ltd's Industry?
How Carbon Intensive is Guangzhou Cai Zhi Lin Corporation Bei Shang Chinese Raw Medicine Co., Ltd's Location?
Guangzhou Cai Zhi Lin Corporation Bei Shang Chinese Raw Medicine Co., Ltd's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Guangzhou Cai Zhi Lin Corporation Bei Shang Chinese Raw Medicine Co., Ltd has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
